Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$7.90M+3696.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Matuszewski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Beta
- 0.26
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.63
Financials
Revenue
$7.90M+3696.0%Net Income
$-8.97MEBITDA
$-7.66MFree Cash Flow
$-5.59MEPS (diluted)
$-0.52Shares Outstanding (diluted)
17.33M+407.8%Operating Expenses
$12.55MCash & Debt
$6.96MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $47.48M | $-6.58M | $-0.39 |
| 2024 | $301.83M | $31.88M | $1.95 |
| 2023 | $16.69M | $-8.48M | $-0.62 |
| 2022 | $6.88M | $-7.19M | $-0.63 |
| 2021 | $4.34M | $-1.45M | $-0.15 |
| 2020 | $2.52M | $-2.39M | $-0.26 |
| 2019 | $2.63M | $-6.38M | $-0.69 |
| 2018 | $1.02M | $-7.59M | $-0.94 |
| 2017 | $328.5K | $-4.84M | $-0.95 |
| 2016 | $592.3K | $-3.56M | $-1.07 |
| 2015 | $151.5K | $-2.38M | $-2.05 |
| 2014 | $31.2K | $-205.6K | $-0.21 |
| 2013 | $15.3K | $-441.8K | $-3.35 |
| 2012 | $806.7K | $-3.33M | $-160.89 |
Valuation
BSEMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-69.39%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·5d ago·Neutral
…gies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent app…
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…unces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company's common stock, Series A warran…
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…tem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC (“Roth”), an affiliate of CR…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…s Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the H.C.
View source ↗ - Newsmarketbeat.com·45d ago·Negative
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
BioStem Technologies to Present at the Sidoti MicroCap Conference POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual Conference.
View source ↗ - Newsmarketbeat.com·54d ago·Negative
BioStem Technologies Q2 Earnings Call Highlights BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Neutral
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.43 per share
Typical surprise -85.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.52 vs $-0.50miss
- Thu, May 14$-0.52 vs $-0.28miss
- Tue, Mar 24$-0.67 vs $0.02miss
- Thu, Nov 13$0.03 vs $0.02beat
- Thu, Aug 14$-0.03 vs $0.32miss
- Mon, May 12$0.17 vs $1.25miss
Estimates and results for BSEM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BSEM officers and directors.
No open-market trades in the recent filings. All 65 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BSEM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.